A Phase 1, Randomized, Multi-center Study to Evaluate the Safety and Immunogenicity of Different Formulations of Vaccines Encoding the RSV Monovalent Antigen or the Flu H5 Antigen in Healthy Participants 18 to 49 Years of Age
Latest Information Update: 26 May 2026
At a glance
- Drugs Influenza virus strain H5N1 vaccine Sanofi (Primary) ; Respiratory syncytial virus monovalent vaccine Sanofi (Primary)
- Indications Influenza A virus H5N1 subtype; Respiratory syncytial virus infections
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Sanofi
Most Recent Events
- 08 May 2026 Status changed from not yet recruiting to recruiting.
- 21 Apr 2026 New trial record